145
Participants
Start Date
March 13, 2017
Primary Completion Date
September 3, 2018
Study Completion Date
August 5, 2022
Levonorgestrel (Kyleena, BAY86-5028)
Low-dose LNG IUS with an initial in vitro release rate of 16 μg LNG/day, used continuously. The total LNG content in LCS16 is 19.5 mg. Administered intrauterine, for 12 months with an option for extended use for up to 5 years
Ethinyl estradiol and drospirenone (Yarina, BAY86-5131)
COC tablet containing 30 μg ethinyl estradiol and 3 mg drospirenone (taken on cycle days 1-21, inclusive, followed by a 7-day tablet-free week) for 12 months
City Clinical Hospital #13 Moscow, Moscow
Regional perinatal center, Yaroslavl
LLC Medical center PRIME ROSE, Saint Petersburg
Smolensk State Medical University, Smolensk
LLC Reafan, Novosibirsk
"Medical Center Avicenna", Novosibirsk
Altai State Medical University, Barnaul
Krasnoyarsk State Medical University, Krasnoyarsk
Scientific Center of family health & human reprod. problems, Irkutsk
Lead Sponsor
Bayer
INDUSTRY